JAZZ vs. BCRX
JAZZ (Jazz Pharmaceuticals plc) and BCRX (BioCryst Pharmaceuticals, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 10 years, JAZZ returned 5.67%/yr vs 8.16%/yr for BCRX. Their 0.28 correlation means their historical movements had little consistent relationship.
Performance
JAZZ vs. BCRX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, JAZZ achieves a 53.86% return, which is significantly higher than BCRX's 16.28% return. Over the past 10 years, JAZZ has underperformed BCRX with an annualized return of 5.67%, while BCRX has yielded a comparatively higher 8.16% annualized return.
JAZZ
- 1D
- -0.02%
- 1M
- 7.13%
- 6M
- 57.84%
- YTD
- 53.86%
- 1Y
- 131.07%
- 3Y*
- 26.20%
- 5Y*
- 11.76%
- 10Y*
- 5.67%
- ALL TIME*
- 15.14%
BCRX
- 1D
- 0.55%
- 1M
- -10.82%
- 6M
- 41.28%
- YTD
- 16.28%
- 1Y
- 8.49%
- 3Y*
- 6.07%
- 5Y*
- -12.43%
- 10Y*
- 8.16%
- ALL TIME*
- 1.16%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $28.03M | $37.18M | $45.64M | |
| $225.74M | $196.10M | $205.87M |
JAZZ vs. BCRX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
JAZZ Jazz Pharmaceuticals plc | 53.86% | 38.04% | 0.12% | -22.79% | 25.05% | -22.81% | 10.56% | 20.43% | -7.94% | 23.50% |
BCRX BioCryst Pharmaceuticals, Inc. | 16.28% | 3.72% | 25.54% | -47.82% | -17.11% | 85.91% | 115.94% | -57.25% | 64.36% | -22.43% |
Correlation
The correlation between JAZZ and BCRX is 0.23, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.23 |
Correlation (3Y) Balances recent behavior with more history. | 0.28 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.31 |
Correlation (10Y) Provides a long-term view across more market conditions. | 0.28 |
Correlation (All Time) Calculated using the full available price history since Jun 1, 2007 | 0.28 |
Fundamentals
JAZZ:
$16.43B
BCRX:
$2.31B
JAZZ:
$14.58
BCRX:
-$1.63
JAZZ:
3.67
BCRX:
2.28
JAZZ:
$4.60B
BCRX:
$940.61M
JAZZ:
$2.80B
BCRX:
$221.20M
JAZZ:
$1.31B
BCRX:
-$303.18M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
JAZZ vs. BCRX — Risk / Return Rank
JAZZ
BCRX
JAZZ vs. BCRX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Jazz Pharmaceuticals plc (JAZZ) and BioCryst Pharmaceuticals, Inc. (BCRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| JAZZ | BCRX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +3.33 | ||
| Sortino ratioReturn per unit of downside risk | +4.41 | ||
| Omega ratioGain probability vs. loss probability | 1.65 | 1.07 | +0.57 |
| Calmar ratioReturn relative to maximum drawdown | 11.55 | 0.31 | +11.24 |
| Martin ratioReturn relative to average drawdown | 29.14 | 0.64 | +28.50 |
Loading charts...
Drawdowns
JAZZ vs. BCRX - Drawdown Comparison
The maximum JAZZ drawdown since its inception was -96.90%, roughly equal to the maximum BCRX drawdown of -97.74%. Use the drawdown chart below to compare losses from any high point for JAZZ and BCRX.
Loading charts...
Drawdown Indicators
| JAZZ | BCRX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.90% | -97.74% | +0.84% |
Max Drawdown (1Y)Largest decline over 1 year | -11.42% | -27.44% | +16.02% |
Max Drawdown (3Y)Largest decline over 3 years | -32.71% | -46.01% | +13.30% |
Max Drawdown (5Y)Largest decline over 5 years | -42.03% | -79.10% | +37.07% |
Max Drawdown (10Y)Largest decline over 10 years | -52.10% | -83.69% | +31.59% |
Current DrawdownCurrent decline from peak | -0.02% | -72.62% | +72.60% |
Average DrawdownAverage peak-to-trough decline | -27.19% | -69.65% | +42.46% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 4.54% | 13.21% | -8.67% |
Volatility
JAZZ vs. BCRX - Volatility Comparison
The current volatility for Jazz Pharmaceuticals plc (JAZZ) is 8.21%, while BioCryst Pharmaceuticals, Inc. (BCRX) has a volatility of 11.22%. This indicates that JAZZ experiences smaller price fluctuations and is considered to be less risky than BCRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| JAZZ | BCRX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.21% | 11.22% | -3.01% |
Volatility (6M)Calculated over the trailing 6-month period | 23.12% | 35.77% | -12.65% |
Volatility (1Y)Calculated over the trailing 1-year period | 37.57% | 46.22% | -8.65% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 31.63% | 62.12% | -30.49% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 32.73% | 72.50% | -39.77% |
Dividends
JAZZ vs. BCRX - Dividend Comparison
Neither JAZZ nor BCRX has paid dividends to shareholders.
Financials
JAZZ vs. BCRX - Financials Comparison
This section allows you to compare key financial metrics between Jazz Pharmaceuticals plc and BioCryst Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
JAZZ vs. BCRX - Profitability Comparison
JAZZ - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Jazz Pharmaceuticals plc reported a gross profit of 0.00 and revenue of 1.21B. Therefore, the gross margin over that period was 0.0%.
BCRX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, BioCryst Pharmaceuticals, Inc. reported a gross profit of 214.41M and revenue of 218.25M. Therefore, the gross margin over that period was 98.2%.
JAZZ - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Jazz Pharmaceuticals plc reported an operating income of 248.20M and revenue of 1.21B, resulting in an operating margin of 20.5%.
BCRX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, BioCryst Pharmaceuticals, Inc. reported an operating income of 98.47M and revenue of 218.25M, resulting in an operating margin of 45.1%.
JAZZ - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Jazz Pharmaceuticals plc reported a net income of 192.80M and revenue of 1.21B, resulting in a net margin of 16.0%.
BCRX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, BioCryst Pharmaceuticals, Inc. reported a net income of 78.40M and revenue of 218.25M, resulting in a net margin of 35.9%.
Frequently Asked Questions
JAZZ and BCRX have a correlation of 0.23, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
BCRX has higher volatility (11.22%) compared to JAZZ (8.21%). In terms of maximum drawdown, JAZZ dropped -96.90% vs BCRX's -97.74%.
JAZZ currently has the higher Sharpe Ratio (3.52 vs 0.19), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for JAZZ and BCRX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer